Screener
Gyre Therapeutics, Inc. GYRE Net Income
Net Income at other companies
Other financials
Where this comes from
Reported directly by Gyre Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic.
The source filing: Gyre Therapeutics, Inc.’s 10-Q, filed August 7, 2026.
- Filed
- Aug 7, 2026, 5:00 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-340448
| Line item | Three Months Ended June 30, | Six Months Ended June 30, |
|---|---|---|
| Net (loss) income | (2,237)) | 2,702) |
| Accretion of Cullgen redeemable convertible preferred stock | (2,642)) | (5,220)) |
| Net loss attributable to noncontrolling interest | (2,835)) | (2,644)) |
| Net (loss) income attributable to common stockholders | $$(2,044)) | $$126) |
| Net (loss) income per share attributable to common stockholders: | ||
| Basic | $$(0.02)) | $$0.00) |
| Diluted | $$(0.03)) | $$(0.03)) |
| Weighted average shares used in calculating net (loss) income per share attributable to common stockholders: |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Gyre Therapeutics, Inc.'s net income?
- Gyre Therapeutics, Inc. (GYRE) reported net income of -$11.66M in Q2 2026.
- How has Gyre Therapeutics, Inc.'s net income changed year-over-year?
- Gyre Therapeutics, Inc.'s net income decreased by 470.6% year-over-year, from -$2.04M to -$11.66M.
- What is the long-term trend for Gyre Therapeutics, Inc.'s net income?
- Over 3 years (2021 to 2025), Gyre Therapeutics, Inc.'s net income has grown at a -61.5% compound annual growth rate (CAGR), from -$87.93M to $5.03M.
- What does net income mean?
- The bottom line — total revenue minus all expenses, taxes, and costs. Represents the profit attributable to the company's shareholders after all obligations are met.
Ask your AI about Gyre Therapeutics, Inc.'s net income.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude